A breakthrough in non-invasive cancer treatment that uses your body’s own biology to fight tumors — safely, selectively, and effectively.
Key Med
Oleander Medical Technologies is responsible for the scientific research, intellectual property, and development of Targeted Osmotic Lysis (TOL). Patient intake, evaluation and treatment are conducted independently by licensed medical professionals through our clinical partner, Key Med.
